Lipoproteins and lipoprotein mimetics for imaging and drug delivery

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 116-131

  Thaxton, C Shad ^a,b   Rink, Jonathan S ^a,b   Naha, Pratap C ^c   Cormode, David P ^c,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Computed tomography; Drug delivery; Fluorescence imaging; High density lipoprotein; Low density lipoprotein; MRI; Photodynamic therapy; siRNA

Indexed keywords

BIOCOMPATIBILITY; BORON; COMPUTERIZED TOMOGRAPHY; CONTRAST MEDIA; DRUG DELIVERY; DRUG THERAPY; GENE THERAPY; LIPIDS; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; NUCLEIC ACIDS; PHOTODYNAMIC THERAPY; PHOTOSENSITIZERS; TOMOGRAPHY;

BORON NEUTRON CAPTURE THERAPY; CONTRAST AGENT; DELIVERY VEHICLE; FLUORESCENCE IMAGING; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEINS; NUCLEIC ACID DELIVERIES; SIRNA;

LIPOPROTEINS;

CHYLOMICRON; CONTRAST MEDIUM; GOLD NANOPARTICLE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NANOCRYSTAL; NUCLEIC ACID; VERY LOW DENSITY LIPOPROTEIN; BIOLOGICAL PRODUCT; BIOMIMETIC MATERIAL; DRUG CARRIER; GOLD; LIGAND; LIPOPROTEIN;

AMINO ACID SUBSTITUTION; BORON NEUTRON CAPTURE THERAPY; CHEMICAL COMPOSITION; CHEMICAL LABELING; DRUG DELIVERY SYSTEM; HUMAN; HYDROPHOBICITY; MOLECULAR IMAGING; NONHUMAN; PARTICLE SIZE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; CHEMISTRY; METABOLISM; PHOTOCHEMOTHERAPY; PROCEDURES; X-RAY COMPUTED TOMOGRAPHY;

ANIMALS; BIOLOGICAL PRODUCTS; BIOMIMETIC MATERIALS; BORON NEUTRON CAPTURE THERAPY; CONTRAST MEDIA; DRUG CARRIERS; GOLD; HUMANS; LIGANDS; LIPOPROTEINS; PHOTOCHEMOTHERAPY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84966628837     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.04.020     Document Type: Review

References (218)

1. [1] Kircher, M.F., Willmann, J.K., Molecular body imaging: MR imaging, CT, and US. Part I. Principles. Radiology 263 (2012), 633–643.
2. [2] Arifin, D.R., Kedziorek, D.A., Fu, Y., Chan, K.W.Y., McMahon, M.T., Weiss, C.R., Kraitchman, D.L., Bulte, J.W.M., Microencapsulated cell tracking. NMR Biomed. 26 (2013), 850–859.
3. [3] Cormode, D.P., Naha, P., Fayad, Z.A., Nanoparticle contrast agents for computed tomography: a focus on micelles. Contrast Media Mol. Imaging 9 (2014), 37–52.
4. [4] Mieszawska, A.J., Mulder, W.J.M., Fayad, Z.A., Cormode, D.P., Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol. Pharm. 10 (2013), 831–847.
5. [5] Kircher, M.F., de la Zerda, A., Jokerst, J.V., Zavaleta, C.L., Kempen, P.J., Mittra, E., Pitter, K., Huang, R., Campos, C., Habte, F., Sinclair, R., Brennan, C.W., Mellinghoff, I.K., Holland, E.C., Gambhir, S.S., A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat. Med. 18 (2012), 829–834.
6. [6] Cormode, D.P., Skajaa, T., Fayad, Z.A., Mulder, W.J.M., Nanotechnology in medical imaging: probe design and applications. Arterioscler. Thromb. Vasc. Biol. 29 (2009), 992–1000.
7. [7] Peer, D., Karp, J.M., Hong, S., Farokhzad, O.C., Margalit, R., Langer, R., Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2 (2007), 751–760.
8. [8] Svenson, S., Clinical translation of nanomedicines. Curr. Opin. Solid State Mater. 16 (2012), 287–294.
9. [9] Patrick, M., Abraxane Sales Are Lower Than Expected in 3Q15. 2015.
10. [10] Gianella, A., Jarzyna, P.A., Mani, V., Ramachandran, S., Calcagno, C., Tang, J., Kann, B., Dijk, W.J., Thijssen, V.L., Griffioen, A.W., Storm, G., Fayad, Z.A., Mulder, W.J., Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano 5 (2011), 4422–4433.
11. [11] Allen, T.M., Cullis, P.R., Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65 (2013), 36–48.
12. [12] Torchilin, V.P., Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24 (2007), 1–16.
13. [13] Al-Jamal, W.T., Kostarelos, K., Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc. Chem. Res. 44 (2011), 1094–1104.
14. [14] Elsabahy, M., Wooley, K.L., Design of polymeric nanoparticles for biomedical delivery applications. Chem. Soc. Rev. 41 (2012), 2545–2561.
15. [15] Brannon-Peppas, L., Blanchette, J.O., Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 64 (2012), 206–212.
16. [16] Zhang, L.F., Chan, J.M., Gu, F.X., Rhee, J.W., Wang, A.Z., Radovic-Moreno, A.F., Alexis, F., Langer, R., Farokhzad, O.C., Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2 (2008), 1696–1702.
17. [17] Mandal, B., Bhattacharjee, H., Mittal, N., Sah, H., Balabathula, P., Thoma, L.A., Wood, G.C., Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine: NBM 9 (2013), 474–491.
18. [18] Khandare, J., Calderon, M., Dagia, N.M., Haag, R., Multifunctional dendritic polymers in nanomedicine: opportunities and challenges. Chem. Soc. Rev. 41 (2012), 2824–2848.
19. [19] Balcioglu, M., Rana, M., Yigit, M.V., Doxorubicin loading on graphene oxide, iron oxide and gold nanoparticle hybrid. J. Mater. Chem. B 1 (2013), 6187–6193.
20. [20] Liu, J., Cui, L., Losic, D., Graphene and graphene oxide as new nanocarriers for drug delivery applications. Acta Biomater. 9 (2013), 9243–9257.
21. [21] Libutti, S.K., Paciotti, G.F., Byrnes, A.A., Alexander, H.R., Gannon, W.E., Walker, M., Seidel, G.D., Yuldasheva, N., Tamarkin, L., Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin. Cancer Res. 16 (2010), 6139–6149.
22. [22] Tassa, C., Shaw, S.Y., Weissleder, R., Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc. Chem. Res. 44 (2011), 842–852.
23. [23] Berman, S.M.C., Walczak, P., Bulte, J.W.M., Tracking stem cells using magnetic nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3 (2011), 343–355.
24. [24] Lee, N., Hyeon, T., Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents. Chem. Soc. Rev. 41 (2012), 2575–2589.
25. [25] Naha, P., Al-Zaki, A., Hecht, E.R., Chorny, M., Chhour, P., Blankemeyer, E., Yates, D.M., Witschey, W.R.T., Litt, H.I., Tsourkas, A., Cormode, D.P., Dextran coated bismuth–iron oxide nanohybrid contrast agents for computed tomography and magnetic resonance imaging. J. Mater. Chem. B 2 (2014), 8239–8248.
26. [26] Li, Z.X., Barnes, J.C., Bosoy, A., Stoddart, J.F., Zink, J.I., Mesoporous silica nanoparticles in biomedical applications. Chem. Soc. Rev. 41 (2012), 2590–2605.
27. [27] Vivero-Escoto, J.L., Huxford-Phillips, R.C., Lin, W.B., Silica-based nanoprobes for biomedical imaging and theranostic applications. Chem. Soc. Rev. 41 (2012), 2673–2685.
28. [28] Cormode, D.P., Jarzyna, P.A., Mulder, W.J.M., Fayad, Z.A., Modified natural nanoparticles as contrast agents for medical imaging. Adv. Drug Deliv. Rev. 62 (2010), 329–338.
29. [29] Skajaa, T., Cormode, D.P., Falk, E., Mulder, W.J.M., Fisher, E.A., Fayad, Z.A., High density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30 (2010), 169–176.
30. [30] Damiano, M.G., Mutharasan, R.K., Tripathy, S., McMahon, K.M., Thaxton, C.S., Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Adv. Drug Deliv. Rev. 65 (2013), 649–662.
31. [31] Huang, H., Cruz, W., Chen, J., Zheng, G., Learning from biology: synthetic lipoproteins for drug delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7 (2015), 298–314.
32. [32] Kannan Mutharasan, R., Foit, L., Shad Thaxton, C., High-density lipoproteins for therapeutic delivery systems. J. Mater. Chem. B 4 (2016), 188–197.
33. [33] Schwarz, B., Douglas, T., Development of virus-like particles for diagnostic and prophylactic biomedical applications. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7 (2015), 722–735.
34. [34] Koudelka, K.J., Manchester, M., Chemically modified viruses: principles and applications. Curr. Opin. Chem. Biol. 14 (2010), 810–817.
35. [35] Bennett, K.M., Zhou, H., Sumner, J.P., Dodd, S.J., Bouraoud, N., Doi, K., Star, R.A., Koretsky, A.P., MRI of the basement membrane using charged nanoparticles as contrast agents. Magn. Reson. Med. 60 (2008), 564–574.
36. [36] Zhen, Z.P., Tang, W., Todd, T., Xie, J., Ferritins as nanoplatforms for imaging and drug delivery. Expert Opin. Drug Deliv. 11 (2014), 1913–1922.
37. [37] Bhushan, B., Kumar, S.U., Matai, I., Sachdev, A., Dubey, P., Gopinath, P., Ferritin nanocages: a novel platform for biomedical applications. J. Biomed. Nanotechnol. 10 (2014), 2950–2976.
38. [38] Buehler, D.C., Marsden, M.D., Shen, S., Toso, D.B., Wu, X., Loo, J.A., Zhou, Z.H., Kickhoefer, V.A., Wender, P.A., Zack, J.A., Rome, L.H., Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery. ACS Nano 8 (2014), 7723–7732.
39. [39] Allijn, I.E., Leong, W., Tang, J., Gianella, A., Mieszawska, A.J., Fay, F., Ma, G., Russell, S., Callo, C.B., Gordon, R.E., Korkmaz, E., Post, J.A., Zhao, Y., Gerritsen, H.C., Storm, G., Thran, A., Proksa, R., Daerr, H., Fuster, V., Fisher, E.A., Fayad, Z.A., Mulder, W.J., Cormode, D.P., Gold nanocrystal labeling allows low density lipoprotein imaging from the subcellular to macroscopic level. ACS Nano 7 (2013), 9761–9770.
40. [40] Cormode, D.P., Skajaa, T., van Schooneveld, M.M., Koole, R., Jarzyna, P., Lobatto, M.E., Calcagno, C., Barazza, A., Gordon, R.E., Zanzonico, P., Fisher, E.A., Fayad, Z.A., Mulder, W.J.M., Nanocrystal core high-density lipoproteins: a multimodal molecular imaging contrast agent platform. Nano Lett. 8 (2008), 3715–3723.
41. [41] Vickers, K.C., Sethupathy, P., Baran-Gale, J., Remaley, A.T., Complexity of microRNA function and the role of isomiRs in lipid homeostasis. J. Lipid Res. 54 (2013), 1182–1191.
42. [42] Chen, W., Jarzyna, P.A., van Tilborg, G.A.F., Nguyen, V.A., Cormode, D.P., Klink, A., Griffioen, A.W., Randolph, G.J., Fisher, E.A., Mulder, W.J.M., Fayad, Z.A., RGD-peptide functionalized and reconstituted high density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J. 24 (2010), 1689–1699.
43. [43] Zheng, G., Chen, J., Li, H., Glickson, J.D., Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 17757–17762.
44. [44] Duivenvoorden, R., Tang, J., Cormode, D.P., Mieszawska, A.J., Izquierdo-Garcia, D., Ozcan, C., Otten, M.J., Zaidi, N., Lobatto, M.E., van Rijs, S.M., Priem, B., Kuan, E.L., Martel, C., Hewing, B., Sager, H., Nahrendorf, M., Randolph, G.J., Stroes, E.S.G., Fuster, V., Fisher, E.A., Fayad, Z.A., Mulder, W.J.M., A statin-loaded reconstituted high-density lipoprotein nanoparticle as a targeted therapy for atherosclerotic plaque inflammation. Nat. Commun., 5, 2014, 3065.
45. [45] Song, L., Li, H., Sunar, U., Chen, J., Corbin, I., Yodh, A., Zheng, G., Naphthalocyanine-reconstituted LDL nanoparticles for in vivo cancer imaging and treatment. Int. J. Nanomedicine 2 (2007), 767–774.
46. [46] Davis, M.E., Chen, Z.G., Shin, D.M., Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7 (2008), 771–782.
47. [47] Eisenberg, S., Windmueller, H.G., Levy, R.I., Metabolic fate of rat and human lipoprotein apoproteins in the rat. J. Lipid Res. 14 (1973), 446–458.
48. [48] Segrest, J.P., Garber, D.W., Brouillette, C.G., Harvey, S.C., Anantharamaiah, G.M., The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv. Protein Chem. 45 (1994), 303–369.
49. [49] Havel, R.J., Eder, H.A., Bragdon, J.H., The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34 (1955), 1345–1353.
50. [50] Bricarello, D.A., Smilowitz, J.T., Zivkovic, A.M., German, J.B., Parikh, A.N., Reconstituted lipoprotein: a versatile class of biologically inspired nanostructures. ACS Nano 5 (2011), 42–57.
51. [51] Nichols, A.V., Krauss, R.M., Musliner, T.A., Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol. 128 (1986), 417–431.
52. [52] Yáñez, J.A., Wang, S.W.J., Knemeyer, I.W., Wirth, M.A., Alton, K.B., Intestinal lymphatic transport for drug delivery. Adv. Drug Deliv. Rev. 63 (2011), 923–942.
53. [53] de Faria, E., Fong, L.G., Komaromy, M., Cooper, A.D., Relative roles of the LDL receptor, the LDL receptor-like protein, and hepatic lipase in chylomicron remnant removal by the liver. J. Lipid Res. 37 (1996), 197–209.
54. [54] Shelness, G.S., Sellers, J.A., Very-low-density lipoprotein assembly and secretion. Curr. Opin. Lipidol. 12 (2001), 151–157.
55. [55] Merkel, M., Eckel, R.H., Goldberg, I.J., Lipoprotein lipase: genetics, lipid uptake, and regulation. J. Lipid Res. 43 (2002), 1997–2006.
56. [56] Hegele, R.A., Plasma lipoproteins: genetic influences and clinical implications. Nat. Rev. Genet. 10 (2009), 109–121.
57. [57] Ramasamy, I., Recent advances in physiological lipoprotein metabolism. Clin. Chem. Lab. Med. 52 (2014), 1695–1727.
58. [58] Babiak, J., Rudel, L.L., Lipoproteins and atherosclerosis. Baillieres Clin. Endocrinol. Metab. 1 (1987), 515–550.
59. [59] Rosenson, R.S., Brewer, H.B. Jr., Chapman, M.J., Fazio, S., Hussain, M.M., Kontush, A., Krauss, R.M., Otvos, J.D., Remaley, A.T., Schaefer, E.J., HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 57 (2011), 392–410.
60. [60] Acton, S., Rigotti, A., Landschulz, K.T., Xu, S., Hobbs, H.H., Kriegert, M., Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271 (1996), 518–520.
61. [61] Kontush, A., Lhomme, M., Chapman, M.J., Unraveling the complexities of the HDL lipidome. J. Lipid Res. 54 (2013), 2950–2963.
62. [62] Shah, A.S., Tan, L., Long, J.L., Davidson, W.S., Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J. Lipid Res. 54 (2013), 2575–2585.
63. [63] Naghavi, M., Libby, P., Falk, E., Casscells, S.W., Litovsky, S., Rumberger, J., Badimon, J.J., Stefanadis, C., Moreno, P., Pasterkamp, G., Fayad, Z., Stone, P.H., Waxman, S., Raggi, P., Madjid, M., Zarrabi, A., Burke, A., Yuan, C., Fitzgerald, P.J., Siscovick, D.S., de Korte, C.L., Aikawa, M., Airaksinen, K.E.J., Assmann, G., Becker, C.R., Chesebro, J.H., Farb, A., Galis, Z.S., Jackson, C., Jang, I.K., Koenig, W., Lodder, R.A., March, K., Demirovic, J., Navab, M., Priori, S.G., Rekhter, M.D., Bahr, R., Grundy, S.M., Mehran, R., Colombo, A., Boerwinkle, E., Ballantyne, C., Insull, W., Schwartz, R.S., Vogel, R., Serruys, P.W., Hansson, G.K., Faxon, D.P., Kaul, S., Drexler, H., Greenland, P., Muller, J.E., Virmani, R., Ridker, P.M., Zipes, D.P., Shah, P.K., Willerson, J.T., From vulnerable plaque to vulnerable patient—a call for new definitions and risk assessment strategies: part I. Circulation 108 (2003), 1664–1672.
64. [64] Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., Macfarlane, P.W., McKillop, J.H., Packard, C.J., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333 (1995), 1301–1307.
65. [65] Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II. JAMA, 256, 1986, 2829–2834.
66. [66] Bilheimer, D.W., Grundy, S.M., Brown, M.S., Goldstein, J.L., Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl. Acad. Sci. U. S. A. 80 (1983), 4124–4128.
67. [67] Moore, K.J., Goldberg, I.J., Emerging roles of PCSK9: more than a one-trick pony. Arterioscler. Thromb. Vasc. Biol. 36 (2016), 211–212.
68. [68] Gordon, D.J., Rifkind, B.M., High-density lipoprotein—the clinical implications of recent studies. N. Engl. J. Med. 321 (1989), 1311–1316.
69. [69] Schwartz, G.G., Olsson, A.G., Abt, M., Ballantyne, C.M., Barter, P.J., Brumm, J., Chaitman, B.R., Holme, I.M., Kallend, D., Leiter, L.A., Leitersdorf, E., McMurray, J.J.V., Mundl, H., Nicholls, S.J., Shah, P.K., Tardif, J.-C., Wright, R.S., Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367 (2012), 2089–2099.
70. [70] Glomset, J.A., Wright, J.L., Some properties of a cholesterol esterifying enzyme in human plasma. Biochim. Biophys. Acta 89 (1964), 266–276.
71. [71] Rothblat, G.H., Phillips, M.C., High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol. 21 (2010), 229–238.
72. [72] Firestone, R., Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug. Chem. 5 (1994), 105–113.
73. [73] Rosenson, R.S., Brewer, H.B., Davidson, W.S., Fayad, Z.A., Fuster, V., Goldstein, J., Hellerstein, M., Jiang, X.C., Phillips, M.C., Rader, D.J., Remaley, A.T., Rothblat, G.H., Tall, A.R., Yvan-Charvet, L., Cholesterol efflux and atheroprotection advancing the concept of reverse cholesterol transport. Circulation 125 (2012), 1905–1919.
74. [74] Sabnis, N., Nair, M., Israel, M., McConathy, W.J., Lacko, A.G., Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int. J. Nanomedicine 7 (2012), 975–983.
75. [75] Kingwell, B.A., Chapman, M.J., Kontush, A., Miller, N.E., HDL-targeted therapies: progress, failures and future. Nat. Rev. Drug Discov. 13 (2014), 445–464.
76. [76] Krause, B.R., Remaley, A.T., Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr. Opin. Lipidol. 24 (2013), 480–486.
77. [77] Franceschini, G., Sirtori, C.R., Capurso, A. II, Weisgraber, K.H., Mahley, R.W., A-I Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J. Clin. Invest. 66 (1980), 892–900.
78. [78] Nissen, S.E., Tsunoda, T., Tuzcu, E.M., Schoenhagen, P., Cooper, C.J., Yasin, M., Eaton, G.M., Lauer, M.A., Sheldon, W.S., Grines, C.L., Halpern, S., Crowe, T., Blankenship, J.C., Kerensky, R., Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003), 2292–2300.
79. [79] Nicholls, S.J., Uno, K., Kataoka, Y., Nissen, S.E., ETC-216 for coronary artery disease. Expert. Opin. Biol. Ther. 11 (2011), 387–394.
80. [80] Lerch, P.G., Fortsch, V., Hodler, G., Bolli, R., Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang. 71 (1996), 155–164.
81. [81] Tardif, J.C., Gregoire, J., L'Allier, P.L., Ibrahim, R., Lesperance, J., Heinonen, T.M., Kouz, S., Berry, C., Basser, R., Lavoie, M.A., Guertin, M.C., Rodes-Cabau, J., Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 (2007), 1675–1682.
82. [82] Easton, R., Gille, A., D'Andrea, D., Davis, R., Wright, S.D., Shear, C., A multiple ascending dose study of CSL112, an infused formulation of apoA-I. J. Clin. Pharmacol. 54 (2014), 301–310.
83. [83] Gille, A., Easton, R., D'Andrea, D., Wright, S.D., Shear, C.L., CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscler. Thromb. Vasc. Biol. 34 (2014), 2106–2114.
84. [84] Calkin, A.C., Drew, B.G., Ono, A., Duffy, S.J., Gordon, M.V., Schoenwaelder, S.M., Sviridov, D., Cooper, M.E., Kingwell, B.A., Jackson, S.P., Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 120 (2009), 2095–2104.
85. [85] Tardif, J.C., Ballantyne, C.M., Barter, P., Dasseux, J.L., Fayad, Z.A., Guertin, M.C., Kastelein, J.J., Keyserling, C., Klepp, H., Koenig, W., L'Allier, P.L., Lesperance, J., Luscher, T.F., Paolini, J.F., Tawakol, A., Waters, D.D., C.H.D.L.I.S.Q.A.R. Investigators, Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur. Heart J. 35 (2014), 3277–3286.
86. [86] Hovingh, G.K., Smits, L.P., Stefanutti, C., Soran, H., Kwok, S., de Graaf, J., Gaudet, D., Keyserling, C.H., Klepp, H., Frick, J., Paolini, J.F., Dasseux, J.L., Kastelein, J.J., Stroes, E.S., The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: the Modifying Orphan Disease Evaluation (MODE) study. Am. Heart J. 169 (2015), 736–742 (e731).
87. [87] Rensen, P.C.N., de Vrueh, R.L.A., Kuiper, J., Bijsterbosch, M.K., Biessen, E.A.L., van Berkel, T.J.C., Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv. Drug Deliv. Rev. 47 (2001), 251–276.
88. [88] Geninatti Crich, S., Lanzardo, S., Alberti, D., Belfiore, S., Ciampa, A., Giovenzana, G.B., Lovazzano, C., Pagliarin, R., Aime, S., Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles. Neoplasia 9 (2007), 1046–1056.
89. [89] Fischer, N.O., Weilhammer, D.R., Dunkle, A., Thomas, C., Hwang, M., Corzett, M., Lychak, C., Mayer, W., Urbin, S., Collette, N., Chiun Chang, J., Loots, G.G., Rasley, A., Blanchette, C.D., Evaluation of nanolipoprotein particles (NLPs) as an in vivo delivery platform. PLoS One, 9, 2014, e93342.
90. [90] Chen, W., Cormode, D.P., Vengrenyuk, Y., Herranz, B., Feig, J.E., A. Klink, Mulder, W.J.M., Fisher, E.A., Fayad, Z.A., Collagen-specific peptide conjugated high density lipoprotein nanoparticles as MRI contrast agents to evaluate the stabilization of atherosclerotic plaque under regression conditions. J. Am. Coll. Cardiol. Img. 6 (2013), 373–384.
91. [91] Frias, J.C., Williams, K.J., Fisher, E.A., Fayad, Z.A., Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J. Am. Chem. Soc. 126 (2004), 16316–16317.
92. [92] McMahon, K.M., Mutharasan, R.K., Tripathy, S., Veliceasa, D., Bobeica, M., Shumaker, D.K., Luthi, A.J., Helfand, B.T., Ardehali, H., Mirkin, C.A., Volpert, O., Thaxton, C.S., Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett. 11 (2011), 1208–1214.
93. [93] Song, Q., Huang, M., Yao, L., Wang, X., Gu, X., Chen, J., Chen, J., Huang, J., Hu, Q., Kang, T., Rong, Z., Qi, H., Zheng, G., Chen, H., Gao, X., Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer's disease by accelerating the clearance of amyloid-beta. ACS Nano 8 (2014), 2345–2359.
94. [94] Frias, J.C., Ma, Y., Williams, K.J., Fayad, Z.A., Fisher, E.A., Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett. 6 (2006), 2220–2224.
95. 89Zr-labeled high-density lipoprotein nanoparticles. J. Nucl. Med. 56 (2015), 1272–1277.
96. [96] Cormode, D.P., Roessl, E., Thran, A., Skajaa, T., Gordon, R.E., Schlomka, J.P., Fuster, V., Fisher, E.A., Mulder, W.J.M., Proksa, R., Fayad, Z.A., Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology 256 (2010), 774–782.
97. [97] Navab, M., Anantharamaiah, G.M., Reddy, S.T., Fogelman, A.M., Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat. Clin. Pract. Cardiovasc. Med. 3 (2006), 540–547.
98. [98] Cormode, D.P., Briley-Saebo, K.C., Mulder, W.J.M., Aguinaldo, J.G.S., Barazza, A., Ma, Y., Fisher, E.A., Fayad, Z.A., An apoA-I mimetic peptide HDL-based MRI contrast agent for atherosclerotic plaque composition detection. Small 4 (2008), 1437–1444.
99. [99] Zhang, Z., Cao, W., Jin, H., Lovell, J.F., Yang, M., Ding, L., Chen, J., Corbin, I., Luo, Q., Zheng, G., Biomimetic nanocarrier for direct cytosolic drug delivery. Angew. Chem. 48 (2009), 9171–9175.
100. [100] Sanchez-Gaytan, B.L., Fay, F., Lobatto, M.E., Tang, J., Ouimet, M., Kim, Y., van der Staay, S.E., van Rijs, S.M., Priem, B., Zhang, L., Fisher, E.A., Moore, K.J., Langer, R., Fayad, Z.A., Mulder, W.J., HDL-mimetic PLGA nanoparticle to target atherosclerosis plaque macrophages. Bioconjug. Chem. 26 (2015), 443–451.
101. [101] Nikanjam, M., Blakely, E.A., Bjornstad, K.A., Shu, X., Budinger, T.F., Forte, T.M., Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int. J. Pharm. 328 (2006), 86–94.
102. [102] Cormode, D.P., Fisher, E.A., Stroes, E.S., Mulder, W.J., Fayad, Z.A., High-density lipoprotein is a nanoparticle, but not all nanoparticles are high-density lipoprotein. Proc. Natl. Acad. Sci. U. S. A., 110, 2013, E3548.
103. [103] Shaish, A., Keren, G., Chouraqui, P., Levkovitz, H., Harats, D., Imaging of aortic atherosclerotic lesions by 125I-LDL, 125I-oxidized-LDL, 125I-HDL and 125I-BSA. Pathobiology 69 (2001), 225–229.
104. [104] D.P. Cormode, R. Chandrasekar, A. Delshad, K.C. Briley-Saebo, C. Calcagno, A. Barazza, W.J.M. Mulder, E.A. Fisher, Z.A. Fayad, Comparison of synthetic HDL contrast agents for MR imaging of atherosclerosis, Bioconjug. Chem., 20 (2009) 937‚ (Äì943).
105. [105] Skajaa, T., Cormode, D.P., Jarzyna, P.A., Delshad, A., Blachford, C., Barazza, A., Fisher, E.A., Gordon, R.E., Fayad, Z.A., Mulder, W.J.M., The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. Biomaterials 32 (2011), 206–213.
106. [106] Skajaa, T., Zhao, Y., van den Heuvel, D.J., Gerritsen, H.C., Cormode, D.P., Koole, R., van Schooneveld, M.M., Post, J.A., Fisher, E.A., Fayad, Z.A., de Mello Donega, C., Mulder, W.J.M., Quantum dot and Cy5.5 labeled nanoparticles to investigate lipoprotein biointeractions via Förster resonance energy transfer. Nano Lett. 10 (2010), 5131–5138.
107. [107] Kim, Y., Fay, F., Cormode, D.P., Sanchez-Gaytan, B.L., Tang, J., Hennessy, E.J., Ma, M., Moore, K., Farokhzad, O.C., Fisher, E.A., Mulder, W.J., Langer, R., Fayad, Z.A., Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics. ACS Nano 7 (2013), 9975–9983.
108. [108] Briley-Saebo, K.C., Geninatti Crich, S., Cormode, D.P., Barazza, A., Mulder, W.J.M., Chen, W., Giovenzana, G.B., Fisher, E.A., Aime, S., Fayad, Z.A., High-relaxivity gadolinium-modified high-density lipoproteins as magnetic resonance imaging contrast agents. J. Phys. Chem. B 113 (2009), 6283–6289.
109. [109] Chen, W., Vucic, E., Leupold, E., Mulder, W.J.M., Cormode, D.P., Briley-Saebo, K.C., Barazza, A., Fisher, E.A., Dathe, M., Fayad, Z.A., Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol. Imaging 3 (2008), 233–242.
110. [110] Carney, C.E., Lenov, I.L., Baker, C.J., MacRenaris, K.W., Eckermann, A.L., Sligar, S.G., Meade, T.J., Nanodiscs as a modular platform for multimodal MR-optical imaging. Bioconjug. Chem. 26 (2015), 899–905.
111. [111] Sigalov, A.B., Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages. Contrast Media Mol. Imaging 9 (2014), 372–382.
112. [112] Lagerstedt, J.O., Petrlova, J., Hilt, S., Marek, A., Chung, Y., Sriram, R., Budamagunta, M.S., Desreux, J.F., Thonon, D., Jue, T., Smirnov, A.I., Voss, J.C., EPR assessment of protein sites for incorporation of Gd(III) MRI contrast labels. Contrast Media Mol. Imaging 8 (2013), 252–264.
113. [113] Rui, M., Guo, W., Ding, Q., Wei, X., Xu, J., Xu, Y., Recombinant high-density lipoprotein nanoparticles containing gadolinium-labeled cholesterol for morphologic and functional magnetic resonance imaging of the liver. Int. J. Nanomedicine 7 (2012), 3751–3768.
114. [114] Sriram, R., Lagerstedt, J.O., Petrlova, J., Samardzic, H., Kreutzer, U., Xie, H., Kaysen, G.A., Desreux, J.F., Thonon, D., Jacques, V., Van Loane, M., Rutledge, J.C., Oda, M.N., Voss, J.C., Jue, T., Imaging apolipoprotein AI in vivo. NMR Biomed. 24 (2011), 916–924.
115. [115] Wang, Q., Chen, S., Luo, Q., Liu, M., Zhou, X., A europium–lipoprotein nanocomposite for highly-sensitive MR-fluorescence multimodal imaging. RSC Adv. 5 (2015), 1808–1811.
116. [116] Cao, W., Ng, K.K., Corbin, I., Zhang, Z., Ding, L., Chen, J., Zheng, G., Synthesis and evaluation of a stable bacteriochlorophyll-analog and its incorporation into high-density lipoprotein nanoparticles for tumor imaging. Bioconjug. Chem. 20 (2009), 2023–2031.
117. [117] Ozawa, T., Yoshimura, H., Kim, S.B., Advances in fluorescence and bioluminescence imaging. Anal. Chem. 85 (2013), 590–609.
118. [118] White, C.R., Garber, D.W., Anantharamaiah, G.M., Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review. J. Lipid Res. 55 (2014), 2007–2021.
119. [119] Chen, L., Yang, G., Monslow, J., Todd, L., Cormode, D.P., Tang, J., Grant, G.R., DeLong, J.H., Tang, S.Y., Lawson, J.A., Pure, E., FitzGerald, G.A., Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 6828–6833.
120. [120] Cui, L., Lin, Q., Jin, C.S., Jiang, W., Huang, H., Ding, L., Muhanna, N., Irish, J.C., Wang, F., Chen, J., Zheng, G., A PEGylation-free biomimetic porphyrin nanoplatform for personalized cancer theranostics. ACS Nano 9 (2015), 4484–4495.
121. [121] Rieffel, J., Chitgupi, U., Lovell, J.F., Recent advances in higher-order, multimodal, biomedical imaging agents. Small 11 (2015), 4445–4461.
122. [122] Corbin, I.R., Ng, K.K., Ding, L., Jurisicova, A., Zheng, G., Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine (London) 8 (2013), 875–890.
123. [123] Zhang, Z., Chen, J., Ding, L., Jin, H., Lovell, J.F., Corbin, I.R., Cao, W., Lo, P.C., Yang, M., Tsao, M.S., Luo, Q., Zheng, G., HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 6 (2010), 430–437.
124. [124] Jung, C., Kaul, M.G., Bruns, O.T., Ducic, T., Freund, B., Heine, M., Reimer, R., Meents, A., Salmen, S.C., Weller, H., Nielsen, P., Adam, G., Heeren, J., Ittrich, H., Intraperitoneal injection improves the uptake of nanoparticle-labeled high-density lipoprotein to atherosclerotic plaques compared with intravenous injection: a multimodal imaging study in ApoE knockout mice. Circ. Cardiovasc. Imaging 7 (2014), 303–311.
125. [125] Pietzsch, J., Bergmann, R., Rode, K., Hultsch, C., Pawelke, B., Wuest, F., van den Hoff, J., Fluorine-18 radiolabeling of low-density lipoproteins: a potential approach for characterization and differentiation of metabolism of native and oxidized low-density lipoproteins in vivo. Nucl. Med. Biol. 31 (2004), 1043–1050.
126. [126] Rosen, J.M., Butler, S.P., Meinken, G.E., Wang, T.S.T., Ramakrishnan, R., Srivastava, S.C., Alderson, P.O., Ginsberg, H.N., Indium-111-labeled LDL: a potential agent for imaging atherosclerotic disease and lipoprotein biodistribution. J. Nucl. Med. 31 (1990), 343–350.
127. [127] Ginsberg, H.N., Goldsmith, S.J., Vallabajosula, S., Noninvasive imaging of 99mTechnetium-labeled low density lipoprotein uptake by tendon xanthomas in hypercholesterolemic patients. Arteriosclerosis 10 (1990), 256–262.
128. [128] Sinzinger, H., Bergmann, H., Kaliman, J., Angelberger, P., Imaging of human atherosclerosis lesions using I-123 low-density-lipoprotein. Eur. J. Nucl. Med. 12 (1986), 291–292.
129. [129] Iuliano, L., Signore, A., Vallabajosula, S., Colavita, A.R., Camastra, C., Ronga, G., Alessandri, C., Sbarigia, E., Fiorani, P., Violi, F., Preparation and biodistribution of (99m)technetium labelled oxidized LDL in man. Atherosclerosis 126 (1996), 131–141.
130. [130] Zheng, G., Li, H., Zhang, M., Lund-Katz, S., Chance, B., Glickson, J.D., Low-density lipoprotein reconstituted by pyropheophorbide cholesteryl oleate as target-specific photosensitizer. Bioconjug. Chem. 13 (2002), 392–396.
131. [131] Wu, S.P., Lee, I., Ghoroghchian, P.P., Frail, P.R., Zheng, G., Glickson, J.D., Therien, M.J., Near-infrared optical Imaging of B16 melanoma cells via low-density lipoprotein-mediated uptake and delivery of high emission dipole strength tris[(porphinato)zinc(II)] fluorophores. Bioconjug. Chem. 16 (2005), 542–550.
132. [132] Li, H., Zhang, Z., Blessington, D., Nelson, D.S., Zhou, R., Lund-Katz, S., Chance, B., Glickson, J.D., Zheng, G., Carbocyanine labeled LDL for optical imaging of tumors. Acad. Radiol. 11 (2004), 669–677.
133. [133] Mitsumori, L.M., Ricks, J.L., Rosenfeld, M.E., Schmiedl, U.P., Yuan, C., Development of a lipoprotein based molecular imaging MR contrast agent for the noninvasive detection of early atherosclerotic disease. Int. J. Cardiovasc. Imaging 20 (2004), 561–567.
134. [134] Drahoš, B., Lukeš, I., Tóth, E., Manganese(II) complexes as potential contrast agents for MRI. Eur. J. Inorg. Chem. 2012 (2012), 1975–1986.
135. [135] Li, H., Gray, B.D., Corbin, I.R., Lebherz, C., Choi, H., Lund-Katz, S., Wilson, J.M., Glickson, J.D., Zhou, R., MR and fluorescent imaging of low-density lipoprotein receptors. Acad. Radiol. 11 (2004), 1251–1259.
136. [136] Corbin, I.R., Li, H., Chen, J., Lund-Katz, S., Zhou, R., Glickson, J.D., Zheng, G., Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia 8 (2006), 488–498.
137. [137] Lowell, A.N., Qiao, H., Liu, T., Ishikawa, T., Zhang, H., Oriana, S., Wang, M., Ricciotti, E., FitzGerald, G.A., Zhou, R., Yamakoshi, Y., Functionalized low-density lipoprotein nanoparticles for in vivo enhancement of atherosclerosis on magnetic resonance images. Bioconjug. Chem. 23 (2012), 2313–2319.
138. [138] Yamakoshi, Y., Qiao, H., Lowell, A.N., Woods, M., Paulose, B., Naka, Y., Zhang, H., Liu, T., Lund-Katz, S., Zhou, R., LDL-based nanoparticles for contrast enhanced MRI of atheroplaques in mouse models. Chem. Commun. 47 (2011), 8835–8837.
139. [139] Chen, J., Corbin, I.R., Li, H., Cao, W., Glickson, J.D., Zheng, G., Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. J. Am. Chem. Soc. 129 (2007), 5798–5799.
140. [140] Hill, M.L., Corbin, I.R., Levitin, R.B., Cao, W., Mainprize, J.G., Yaffe, M.J., Zheng, G., In vitro assessment of poly-iodinated triglyceride reconstituted low-density lipoprotein: initial steps toward CT molecular imaging. Acad. Radiol. 17 (2010), 1359–1365.
141. [141] Krieger, M., Reconstitution of the hydrophobic core of low-density lipoprotein. Methods Enzymol. 128 (1986), 608–613.
142. [142] Ishibashi, S., Brown, M.S., Goldstein, J.L., Gerard, R.D., Hammer, R.E., Herz, J., Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92 (1993), 883–893.
143. [143] Huettinger, M., Corbett, J.R., Schneider, W.J., Willerson, J.T., Brown, M.S., Goldstein, J.L., Imaging of hepatic low-density lipoprotein receptors by radionuclide scintiscanning in vivo. Proc. Natl. Acad. Sci. U. S. A. 81 (1984), 7599–7603.
144. [144] Barazza, A., Blachford, C., Even-Or, O., Joaquin, V.A., Briley-Saeboe, K.C., Chen, W., Jiang, X.-C., Mulder, W.J.M., Cormode, D.P., Fayad, Z.A., Fisher, E.A., The complex fate in plasma of gadolinium incorporated into high-density lipoproteins used for magnetic imaging of atherosclerotic plaques. Bioconjug. Chem. 24 (2013), 1039–1048.
145. [145] Xu, N., Zhou, L., Odselius, R., Nilsson, A., Uptake of radiolabeled and colloidal gold-labeled chyle chylomicrons and chylomicron remnants by rat platelets in vitro. Arterioscler. Thromb. Vasc. Biol. 15 (1995), 972–981.
146. [146] Bowler, A., Redgrave, T.G., Mamo, J.C.L., Chylomicron-remnant clearance in homozygote and heterozygote Watanabe-heritable-hyperlipidaemic rabbits is defective. Lack of evidence for an independent chylomicron-remnant receptor. Biochem. J. 276 (1991), 381–386.
147. [147] Bruns, O.T., Ittrich, H., Peldschus, K., Kaul, M.G., Tromsdorf, U.I., Lauterwasser, J., Nikolic, M.S., Mollwitz, B., Merkel, M., Bigall, N.C., Sapra, S., Reimer, R., Hohenberg, H., Weller, H., Eychmuller, A., Adam, G., Beisiegel, U., Heeren, J., Real-time magnetic resonance imaging and quantification of lipoprotein metabolism in vivo using nanocrystals. Nat. Nanotechnol. 4 (2009), 193–201.
148. [148] Huynh, E., Zheng, G., Engineering multifunctional nanoparticles: all-in-one versus one-for-all. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5 (2013), 250–265.
149. [149] Sabnis, N., Lacko, A.G., Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. Ther. Deliv. 3 (2012), 599–608.
150. [150] Tanaka, T., Shiramoto, S., Miyashita, M., Fujishima, Y., Kaneo, Y., Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int. J. Pharm. 277 (2004), 39–61.
151. [151] Prabhakar, U., Maeda, H., Jain, R.K., Sevick-Muraca, E.M., Zamboni, W., Farokhzad, O.C., Barry, S.T., Gabizon, A., Grodzinski, P., Blakey, D.C., Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73 (2013), 2412–2417.
152. [152] Klibanov, A.L., Maruyama, K., Beckerleg, A.M., Torchilin, V.P., Huang, L., Activity of amphipathic poly(ethylene glycol)-5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta 1062 (1991), 142–148.
153. [153] Danilo, C., Gutierrez-Pajares, J.L., Mainieri, M.A., Mercier, I., Lisanti, M.P., Frank, P.G., Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development. Breast Cancer Res., 15, 2013, R87.
154. [154] Gorin, A., Gabitova, L., Astsaturov, I., Regulation of cholesterol biosynthesis and cancer signaling. Curr. Opin. Pharmacol. 12 (2012), 710–716.
155. [155] Leon, C.G., Locke, J.A., Adomat, H.H., Etinger, S.L., Twiddy, A.L., Neumann, R.D., Nelson, C.C., Guns, E.S., Wasan, K.M., Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 70 (2010), 390–400.
156. [156] Llaverias, G., Danilo, C., Mercier, I., Daumer, K., Capozza, F., Williams, T.M., Sotgia, F., Lisanti, M.P., Frank, P.G., Role of cholesterol in the development and progression of breast cancer. Am. J. Pathol. 178 (2011), 402–412.
157. [157] Muntoni, S., Atzori, L., Mereu, R., Satta, G., Macis, M.D., Congia, M., Tedde, A., Desogus, A., Muntoni, S., Serum lipoproteins and cancer. Nutr. Metab. Cardiovasc. Dis. 19 (2009), 218–225.
158. [158] Shahzad, M.M.K., Mangala, L.S., Han, H.D., Lu, C.H., Bottsford-Miller, J., Nishimura, M., Mora, E.M., Lee, J.W., Stone, R.L., Pecot, C.V., Thanapprapasr, D., Roh, J.W., Gaur, P., Nair, M.P., Park, Y.Y., Sabnis, N., Deavers, M.T., Lee, J.S., Ellis, L.M., Lopez-Berestein, G., McConathy, W.J., Prokai, L., Lacko, A.G., Sood, A.K., Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia, 13, 2011, 309-U142.
159. [159] Liadaki, K.N., Liu, T., Xu, S., Ishida, B.Y., Duchateaux, P.N., Krieger, J.P., Kane, J., Krieger, M., Zannis, V.I., Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. J. Biol. Chem. 275 (2000), 21262–21271.
160. [160] Ng, K.K., Lovell, J.F., Zheng, G., Lipoprotein-inspired nanoparticles for cancer theranostics. Acc. Chem. Res. 44 (2011), 1105–1113.
161. [161] Farokhzad, O.C., Langer, R., Impact of nanotechnology on drug delivery. ACS Nano 3 (2009), 16–20.
162. [162] Wang, J., Jia, J., Liu, J., He, H., Zhang, W., Li, Z., Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins. Drug Deliv. 20 (2013), 356–363.
163. [163] Zhang, M., Jia, J., Liu, J., He, H., Liu, L., A novel modified paclitaxel-loaded discoidal recombinant high-density lipoproteins: preparation, characterizations and in vivo evaluation. Asian J. Pharm. Sci. 8 (2013), 11–18.
164. [164] Jia, J., Xiao, Y., Liu, J., Zhang, W., He, H., Chen, L., Zhang, M., Preparation, characterizations, and in vitro metabolic processes of paclitaxel-loaded discoidal recombinant high-density lipoproteins. J. Pharm. Sci. 101 (2012), 2900–2908.
165. [165] Sabnis, N., Pratap, S., Akopova, I., Bowman, P.W., Lacko, A.G., Pre-clinical evaluation of rHDL encapsulated retinoids for the treatment of neuroblastoma. Front. Pediatr., 1, 2013, 6.
166. [166] Wang, B., Yuan, Y., Han, L., Ye, L., Shi, X., Feng, M., Recombinant lipoproteins reinforce cytotoxicity of doxorubicin to hepatocellular carcinoma. J. Drug Target. 22 (2014), 76–85.
167. [167] Yuan, Y., Wang, W., Wang, B., Zhu, H., Zhang, B., Feng, M., Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier. J. Drug Target. 21 (2013), 367–374.
168. [168] Cho, K.H., Rapamycin in lipoproteins for enhanced delivery. Cell Cycle, 11, 2012, 4298.
169. [169] Cho, K.H., Enhanced delivery of rapamycin by V156K-apoA-I high-density lipoprotein inhibits cellular proatherogenic effects and senescence and promotes tissue regeneration. J. Gerontol. A Biol. Sci. Med. Sci. 66 (2011), 1274–1285.
170. [170] Tang, J., Lobatto, M.E., Hassing, L., van der Staay, S., van Rijs, S.M., Calcagno, C., Braza, M.S., Baxter, S., Fay, F., Sanchez-Gaytan, B.L., Duivenvoorden, R., Sager, H.B., Astudillo, Y.M., Leong, W., Ramachandran, S., Storm, G., Perez-Medina, C., Reiner, T., Cormode, D.P., Strijkers, G.J., Stroes, E.S.G., Swirski, F.K., Nahrendorf, M., Fisher, E.A., Fayad, Z.A., Mulder, W.J.M., Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Sci. Adv., 1, 2015, e1400223.
171. [171] Corbin, I.R., Ligand-coupled lipoprotein for ovarian cancer-specific drug delivery. Methods Mol. Biol. 1049 (2013), 467–480.
172. [172] Harisa, G.I., Alanazi, F.K., Low density lipoprotein bionanoparticles: from cholesterol transport to delivery of anti-cancer drugs. Saudi Pharm. J. 22 (2014), 504–515.
173. [173] Makheja, A.N., Bloom, S., Muesing, R., Simon, T., Bailey, J.M., Anti-inflammatory drugs in experimental atherosclerosis. 7. Spontaneous atherosclerosis in WHHL rabbits and inhibition by cortisone acetate. Atherosclerosis 76 (1989), 155–161.
174. [174] Naito, M., Yasue, M., Asai, K., Yamada, K., Hayashi, T., Kuzuya, M., Funaki, C., Yoshimine, N., Kuzuya, F., Effects of dexamethasone on experimental atherosclerosis in cholesterol-fed rabbits. J. Nutr. Sci. Vitaminol. (Tokyo) 38 (1992), 255–264.
175. [175] Asai, K., Funaki, C., Hayashi, T., Yamada, K., Naito, M., Kuzuya, M., Yoshida, F., Yoshimine, N., Kuzuya, F., Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits. Possible mechanisms. Arterioscler. Thromb. 13 (1993), 892–899.
176. [176] Tauchi, Y., Takase, M., Zushida, I., Chono, S., Sato, J., Ito, K., Morimoto, K., Preparation of a complex of dexamethasone palmitate–low density lipoprotein and its effect on foam cell formation of murine peritoneal macrophages. J. Pharm. Sci. 88 (1999), 709–714.
177. [177] Tauchi, Y., Zushida, L., Chono, S., Sato, J., Ito, K., Morimoto, K., Effect of dexamethasone palmitate-low density lipoprotein complex on cholesterol ester accumulation in aorta of atherogenic model mice. Biol. Pharm. Bull. 24 (2001), 925–929.
178. [178] Chu, A.C., Tsang, S.Y., Lo, E.H., Fung, K.P., Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. Life Sci. 70 (2001), 591–601.
179. [179] Nikanjam, M., Gibbs, A.R., Hunt, C.A., Budinger, T.F., Forte, T.M., Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J. Control. Release 124 (2007), 163–171.
180. [180] Radwan, A.A., Alanazi, F.K., Design and synthesis of new cholesterol-conjugated 5-fluorouracil: a novel potential delivery system for cancer treatment. Molecules 19 (2014), 13177–13187.
181. [181] Meng, F., Asghar, S., Gao, S., Su, Z., Song, J., Huo, M., Meng, W., Ping, Q., Xiao, Y., A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer's disease. Colloids Surf. B: Biointerfaces 134 (2015), 88–97.
182. [182] Parhofer, K.G., Hugh, P., Barrett, R., Bier, D.M., Schonfeld, G., Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J. Lipid Res. 32 (1991), 1311–1323.
183. [183] Kader, A., Pater, A., Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J. Control. Release 80 (2002), 29–44.
184. [184] Grundy, S.M., Mok, H.Y., Chylomicron clearance in normal and hyperlipidemic man. Metabolism 25 (1976), 1225–1239.
185. [185] Schaefer, E.J., Jenkins, L.L., Brewer, H.B. Jr., Human chylomicron apolipoprotein metabolism. Biochem. Biophys. Res. Commun. 80 (1978), 405–412.
186. [186] Ahmad, J., Amin, S., Rahman, M., Rub, R.A., Singhal, M., Ahmad, M.Z., Rahman, Z., Addo, R.T., Ahmad, F.J., Mushtaq, G., Kamal, M.A., Akhter, S., Solid matrix based lipidic nanoparticles in oral cancer chemotherapy: applications and pharmacokinetics. Curr. Drug Metab. 16 (2015), 633–644.
187. [187] Han, S., Hu, L., Quach, T., Simpson, J.S., Trevaskis, N.L., Porter, C.J., Constitutive triglyceride turnover into the mesenteric lymph is unable to support efficient lymphatic transport of a biomimetic triglyceride prodrug. J. Pharm. Sci. 105 (2016), 786–796.
188. [188] Makwana, V., Jain, R., Patel, K., Nivsarkar, M., Joshi, A., Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: elucidation of mechanism of uptake using chylomicron flow blocking approach. Int. J. Pharm. 495 (2015), 439–446.
189. [189] Aji Alex, M.R., Chacko, A.J., Jose, S., Souto, E.B., Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur. J. Pharm. Sci. 42 (2011), 11–18.
190. [190] Guo, P., Coban, O., Snead, N.M., Trebley, J., Hoeprich, S., Guo, S., Shu, Y., Engineering RNA for targeted siRNA delivery and medical application. Adv. Drug Deliv. Rev. 62 (2010), 650–666.
191. [191] Rana, T.M., Illuminating the silence: understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell Biol. 8 (2007), 23–36.
192. [192] Weinstein, S., Peer, D., RNAi nanomedicines: challenges and opportunities within the immune system. Nanotechnology, 21, 2010, 232001.
193. [193] McMahon, K.M., Thaxton, C.S., High-density lipoproteins for the systemic delivery of short interfering RNA. Expert Opin. Drug Deliv. 11 (2014), 231–247.
194. [194] Chen, Q., Butler, D., Querbes, W., Pandey, R.K., Ge, P., Maier, M.A., Zhang, L., Rajeev, K.G., Nechev, L., Kotelianski, V., Manoharan, M., Sah, D.W., Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. J. Control. Release 144 (2010), 227–232.
195. [195] DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R.K., Rajeev, K.G., Manoharan, M., Sah, D.W., Zamore, P.D., Aronin, N., Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 17204–17209.
196. [196] Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R.K., Racie, T., Rajeev, K.G., Rohl, I., Toudjarska, I., Wang, G., Wuschko, S., Bumcrot, D., Koteliansky, V., Limmer, S., Manoharan, M., Vornlocher, H.P., Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432 (2004), 173–178.
197. [197] Wolfrum, C., Shi, S., Jayaprakash, K.N., Jayaraman, M., Wang, G., Pandey, R.K., Rajeev, K.G., Nakayama, T., Charrise, K., Ndungo, E.M., Zimmermann, T., Koteliansky, V., Manoharan, M., Stoffel, M., Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25 (2007), 1149–1157.
198. [198] Bijsterbosch, M.K., Rump, E.T., De Vrueh, R.L., Dorland, R., van Veghel, R., Tivel, K.L., Biessen, E.A., van Berkel, T.J., Manoharan, M., Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Nucleic Acids Res. 28 (2000), 2717–2725.
199. [199] Lorenz, C., Hadwiger, P., John, M., Vornlocher, H.P., Unverzagt, C., Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 14 (2004), 4975–4977.
200. [200] Wagner, J., Riwanto, M., Besler, C., Knau, A., Fichtlscherer, S., Roxe, T., Zeiher, A.M., Landmesser, U., Dimmeler, S., Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 1392–1400.
201. [201] Yang, S., Damiano, M.G., Zhang, H., Tripathy, S., Luthi, A.J., Rink, J.S., Ugolkov, A.V., Singh, A.T., Dave, S.S., Gordon, L.I., Thaxton, C.S., Biomimetic, synthetic HDL nanostructures for lymphoma. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 2511–2516.
202. [202] Ding, Y., Wang, W., Feng, M., Wang, Y., Zhou, J., Ding, X., Zhou, X., Liu, C., Wang, R., Zhang, Q., A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 33 (2012), 8893–8905.
203. [203] Ghosh, M., Ren, G., Simonsen, J.B., Ryan, R.O., Cationic lipid nanodisks as an siRNA delivery vehicle. Biochem. Cell Biol. 92 (2014), 200–205.
204. [204] Thaxton, C.S., Daniel, W.L., Giljohann, D.A., Thomas, A.D., Mirkin, C.A., Templated spherical high density lipoprotein nanoparticles. J. Am. Chem. Soc. 131 (2009), 1384–1385.
205. [205] Luthi, A.J., Lyssenko, N.N., Quach, D., McMahon, K.M., Millar, J.S., Vickers, K.C., Rader, D.J., Phillips, M., Mirkin, C.A., Thaxton, C.S., Robust passive and active efflux of cellular cholesterol to a designer functional mimic of high density lipoprotein. J. Lipid Res. 56 (2015), 972–985.
206. [206] Tripathy, S., Vinokour, E., McMahon, K.M., Volpert, O.V., Thaxton, C.S., High density lipoprotein nanoparticles deliver RNAi to endothelial cells to inhibit angiogenesis. Part. Part. Syst. Charact. 31 (2014), 1141–1150.
207. [207] Yang, M., Jin, H., Chen, J., Ding, L., Ng, K.K., Lin, Q., Lovell, J.F., Zhang, Z., Zheng, G., Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles. Small 7 (2011), 568–573.
208. [208] Jin, H., Lovell, J.F., Chen, J., Lin, Q., Ding, L., Ng, K.K., Pandey, R.K., Manoharan, M., Zhang, Z., Zheng, G., Mechanistic insights into LDL nanoparticle-mediated siRNA delivery. Bioconjug. Chem. 23 (2012), 33–41.
209. [209] Zhu, Q.L., Zhou, Y., Guan, M., Zhou, X.F., Yang, S.D., Liu, Y., Chen, W.L., Zhang, C.G., Yuan, Z.Q., Liu, C., Zhu, A.J., Zhang, X.N., Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy. Biomaterials 35 (2014), 5965–5976.
210. [210] Kuwahara, H., Nishina, K., Yoshida, K., Nishina, T., Yamamoto, M., Saito, Y., Piao, W., Yoshida, M., Mizusawa, H., Yokota, T., Efficient in vivo delivery of siRNA into brain capillary endothelial cells along with endogenous lipoprotein. Mol. Ther. 19 (2011), 2213–2221.
211. [211] Boggio, P., Toppino, A., Geninatti Crich, S., Alberti, D., Marabello, D., Medana, C., Prandi, C., Venturello, P., Aime, S., Deagostino, A., The hydroboration reaction as a key for a straightforward synthesis of new MRI-NCT agents. Org. Biomol. Chem. 13 (2015), 3288–3297.
212. [212] Alberti, D., Protti, N., Toppino, A., Deagostino, A., Lanzardo, S., Bortolussi, S., Altieri, S., Voena, C., Chiarle, R., Geninatti Crich, S., Aime, S., A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of boron neutron capture therapy in the lung cancer treatment. Nanomedicine (London) 11 (2015), 741–750.
213. [213] Geninatti-Crich, S., Alberti, D., Szabo, I., Deagostino, A., Toppino, A., Barge, A., Ballarini, F., Bortolussi, S., Bruschi, P., Protti, N., Stella, S., Altieri, S., Venturello, P., Aime, S., MRI-guided neutron capture therapy by use of a dual gadolinium/boron agent targeted at tumour cells through upregulated low-density lipoprotein transporters. Chem. Eur. J. 17 (2011), 8479–8486.
214. [214] Toppino, A., Bova, M.E., Geninatti Crich, S., Alberti, D., Diana, E., Barge, A., Aime, S., Venturello, P., Deagostino, A., A carborane-derivative “click” reaction under heterogeneous conditions for the synthesis of a promising lipophilic MRI/GdBNCT agent. Chem. Eur. J. 19 (2013), 721–728.
215. [215] Barth, R.F., Vicente, M.G.H., Harling, O.K., Kiger, W.S., Riley, K.J., Binns, P.J., Wagner, F.M., Suzuki, M., Aihara, T., Kato, I., Kawabata, S., Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat. Oncol., 7, 2012, 146.
216. [216] Kootte, R.S., Smits, L.P., van der Valk, F.M., Dasseux, J.-L., Keyserling, C.H., Barbaras, R., Paolini, J.F., Santos, R.D., van Dijk, T.H., Dallinga-van Thie, G.M., Nederveen, A.J., Mulder, W.J.M., Hovingh, G.K., Kastelein, J.J.P., Groen, A.K., Stroes, E.S., Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J. Lipid Res. 56 (2015), 703–712.
217. [217] Sieber, M.A., Pietsch, H., Walter, J., Haider, W., Frenzel, T., Weinmann, H.J., A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Investig. Radiol. 43 (2008), 65–75.
218. [218] Kanal, E., Tweedle, M.F., Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology 275 (2015), 630–634.